LDLR and metabolic syndrome: The insulin resistance is associated with dyslipidemia [22] and may affect chylomicron remnant metabolism by down regulating LDL-receptor expression and increasing hepatic cholesterol synthesis and very low-density lipoprotein secretion [23].